Sage Journals: Discover world-class research

Abstract

Purpose

This study evaluated the utilization of acid suppression agents following upper gastrointestinal (GI) bleeding in the state of Michigan.

Methods

A focus group was used to develop a one-page survey that consisted of questions pertaining to acid suppression agents following acute, upper GI bleeding. Survey consistency and validity were established through review by several experienced pharmacists practicing in either critical care or drug information. Surveys were mailed twice (at 30-day intervals) to the director of pharmacy at all hospitals (n = 267) in the state of Michigan.

Results

Completed surveys were received from 76/267 (28.5%) institutions. Sixty-five percent of institutions stated that they had one preferred intravenous (IV) acid suppressive agent for acute GI bleeding, with 59% using a histamine-2 receptor antagonist (H₂RA) and 41% using a proton pump inhibitor (PPI). When an IV PPI was prescribed, only 36% used a continuous infusion dosing regimen. For IV to oral step-down therapy, PPIs were chosen more often than H₂RAs (81% vs 19%). Oral PPI therapy was usually initiated using a capsule/tablet (82%) as opposed to a PPI suspension (18%). Institutional guidelines for acid suppression were in place at only 23% of institutions, although 67% had restrictions for IV PPI use.

Conclusion

Wide variation exists in the use of acid suppressive agents following upper GI bleeding in the state of Michigan.

Keywords

acid supression agents proton pump inhibitors upper gastrointestinal bleeding

Get full access to this article

View all access options for this article.

References

Erstad

B.L.

Proton-pump Inhibitors for acute peptic ulcer bleeding. Ann Pharmacother. 2001; 35: 730–40.

Huggins

R.M.

, Scates

A.C.

, Latour

J.K.

Intravenous proton-pump inhibitors versus H₂-antagonists for treatment of GI bleeding. Ann Pharmacother. 2003; 37: 433–7.

Kupfer

, Cappell

M.S.

, Tessler

Acute gastrointestinal bleeding in the intensive care unit. Gastroent Clin N Amer. 2000; 29(2): 275–307.

Laine

, Peterson

W.L.

Bleeding peptic ulcer. N Engl J Med. 1994; 331: 717–27.

Beejay

, Wolfe

M.M.

Acute gastrointestinal bleeding in the intensive care unit: The gastroenterologist's perspective. Gastroenterol Clin North Am. 2000; 29: 309–36.

Green

F.W.

Jr , Kaplan

M.M.

, Curtis

L.E.

Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978; 74: 38–43.

British Society of Gastroenterology Endoscopy Committee. Nonvariceal upper gastrointestinal haemorrhage: Guidelines. Gut. 2002; 51(suppl IV): iv1–iv6.

Collins

, Langman

Treatment with histamine-2 antagonists in acute upper gastrointestinal hemorrhage. N Engl J Med. 1985; 313: 660–6.

Walt

R.P.

, Cottrell

, Mann

S.G.

Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet. 1992; 340: 1058–62.

10.

Levine

J.E.

, Leontiadis

G.I.

, Sharma

V.K.

Meta-analysis: The efficacy of intravenous H₂-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther. 2002; 16: 1137–42.

11.

Merki

H.S.

, Halter

, Widler-Smith

C.H.

Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine. Gastroenterology. 1993; 105: 748–54.

12.

Netzer

, Gaia

, Sandoz

Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 1999; 94: 351–7.

13.

Hsu

T.C.

, Su

C.F.

, Leu

S.C.

Omeprazole is more effective than a histamine H₂-receptor blocker for maintaining a persistent elevation of gastric pH after colon resection for cancer. Am J Surg. 2004; 187: 20–23.

14.

Brunner

, Chang

Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: An open randomized controlled trial. Digestion. 1990; 45: 217–25.

15.

Daneshmend

T.K.

, Hawkey

C.J.

, Langman

M.J.S.

Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomized double blind controlled trial. BMJ. 1992; 304: 143–7.

16.

Grosso

, Rossi

, Gambitta

Non-bleeding visible vessel treatment: Perendoscopic injection therapy versus omeprazole infusion. Scand J Gastroenterol. 1995; 30: 872–5.

17.

Lanas

, Artal

, Blas

Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol. 1995; 21: 103–6.

18.

Villanueva

, Balanzo

, Torras

Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: A prospective and randomized study. Endoscopy. 1995; 27: 308–12.

19.

Chua

R.T.

, Lin

H.J.

, Wang

Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized controlled study. Chin Med J (Taipei). 1996; 57: 139–45.

20.

Khuroo

M.S.

, Yattoo

G.N.

, Javid

A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 1997; 336: 1054–8.

21.

Schaffalitzky de Muckadell

O.B.

, Havelund

, Harling

Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Scand J Gastroenterol. 1997; 32: 320–7.

22.

Hasselgren

, Lind

, Lundell

Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Scand J Gastroenterol. 1997; 32: 328–33.

23.

Tseng

G.Y.

, Lin

H.J.

, Lin

H.Y.

The influence of intravenous omeprazole on intragastric pH and outcomes in patients with peptic ulcer bleeding after successful endoscopic therapy: A prospective randomized comparative trial. Hepatogastroenterology. 1999; 46: 2183–8.

24.

Lin

H.J.

, Lo

W.C.

, Lee

F.Y.

A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med. 1998; 158: 54–8.

25.

Lau

J.Y.W.

, Sung

J.J.Y.

, Lee

K.K.C.

Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000; 343: 310–16.

26.

Javid

, Masoodi

, Zargar

S.A.

Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med. 2001; 111: 280–4.

27.

Fried

, Beglinger

, Stumpf

Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. Gut. 1999; 45(Suppl 5): A165.

28.

Gisbert

J.P.

, Gonzalez

, Calvet

Proton pump inhibitors versus H₂-antagonists: A meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001; 15: 917–26.

29.

Zed

P.J.

, Loewen

P.S.

, Slavik

R.S.

Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother. 2001; 35: 1528–34.

30.

Barkun

, Bardou

, Marshall

J.K.

Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003; 139: 843–57.

31.

Brunner

, Luna

, Hartmann

Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med. 1996; 69: 225–31.

Use of Acid Suppression Agents following Acute,Nonvariceal,Upper Gastrointestinal Bleeding

Abstract

Purpose

Methods

Results

Conclusion

Keywords

Get full access to this article

References